Uncategorized
Actavis to acquire Allergan in $66 billion transaction
Actavis plans to acquire Allergan in a transaction valued at $66 billion, or $219 per share in cash and Actavis shares.The acquisition would create a top 10 global growth pharmaceutical company with $23 billion in anticipated revenue, Allergan announced in a press release.